Clinical Trials
4 trialsNCT06463665 2026-06-04
VIRO-25
Genelux Corporation
Phase 2 Recruiting
NCT06119581 2026-06-03
SUNRAY-01
Eli Lilly and Company
Phase 3 Recruiting
NCT04222972 2026-03-05
AcceleRET-Lung
Hoffmann-La Roche
Phase 3 Terminated
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting